Short Interest in Klotho Neurosciences, Inc. (NASDAQ:KLTO) Drops By 31.7%

by · The Cerbat Gem

Klotho Neurosciences, Inc. (NASDAQ:KLTO – Get Free Report) was the recipient of a significant drop in short interest in February. As of February 13th, there was short interest totaling 706,392 shares, a drop of 31.7% from the January 29th total of 1,033,627 shares. Based on an average daily trading volume, of 508,114 shares, the short-interest ratio is currently 1.4 days. Currently, 1.1% of the shares of the stock are short sold. Currently, 1.1% of the shares of the stock are short sold. Based on an average daily trading volume, of 508,114 shares, the short-interest ratio is currently 1.4 days.

Wall Street Analyst Weigh In

KLTO has been the topic of a number of analyst reports. Wall Street Zen upgraded Klotho Neurosciences to a “hold” rating in a research report on Saturday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Klotho Neurosciences in a research note on Monday, December 29th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has an average rating of “Sell”.

Check Out Our Latest Analysis on KLTO

Klotho Neurosciences Trading Up 21.5%

NASDAQ KLTO traded up $0.11 during mid-day trading on Monday, hitting $0.65. The company’s stock had a trading volume of 3,529,089 shares, compared to its average volume of 3,886,917. The company’s 50 day simple moving average is $0.31 and its 200 day simple moving average is $0.46. Klotho Neurosciences has a twelve month low of $0.11 and a twelve month high of $3.91. The firm has a market capitalization of $47.48 million, a price-to-earnings ratio of -2.02 and a beta of 9.02.

Institutional Trading of Klotho Neurosciences

Several institutional investors and hedge funds have recently modified their holdings of the stock. Jane Street Group LLC purchased a new stake in Klotho Neurosciences in the 2nd quarter valued at $26,000. XTX Topco Ltd grew its stake in shares of Klotho Neurosciences by 101.2% in the 4th quarter. XTX Topco Ltd now owns 160,569 shares of the company’s stock worth $46,000 after acquiring an additional 80,768 shares in the last quarter. Renaissance Technologies LLC purchased a new stake in shares of Klotho Neurosciences in the fourth quarter valued at about $126,000. Geode Capital Management LLC lifted its position in shares of Klotho Neurosciences by 51.8% during the fourth quarter. Geode Capital Management LLC now owns 491,832 shares of the company’s stock valued at $142,000 after purchasing an additional 167,905 shares in the last quarter. Finally, Brummer Multi Strategy AB bought a new position in shares of Klotho Neurosciences during the fourth quarter valued at about $175,000. 20.07% of the stock is owned by hedge funds and other institutional investors.

About Klotho Neurosciences

(Get Free Report)

Klotho Neurosciences, Inc, a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan’s Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases.

Recommended Stories